Quick Answer
Entera Bio Ltd. reported Research And Development Expense of $6.00 million for the year ending 2025.
- Entera Bio Ltd. showed an increase of +33.5% in Research And Development Expense from 2024 to 2025.
- This data is from Entera Bio Ltd.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.12 million | Q2 2021: $1.23 million | Q3 2021: $1.77 million | Q1 2022: $1.69 million | Q2 2022: $1.39 million | Q3 2022: $1.41 million | Q1 2023: $931.0 thousand | Q2 2023: $1.21 million | Q3 2023: $1.37 million | Q1 2024: $735.0 thousand | Q2 2024: $1.09 million | Q3 2024: $1.48 million | Q1 2025: $1.12 million | Q2 2025: $1.52 million | Q3 2025: $1.64 million.
- Over the full 10 years of available data (2016 to 2025), Entera Bio Ltd.'s Research And Development Expense has grown by 126.7%.
- Historical annual values: Fiscal year 2025: $6.00 million | Fiscal year 2024: $4.50 million | Fiscal year 2023: $4.51 million | Fiscal year 2022: $5.85 million | Fiscal year 2021: $6.77 million | Fiscal year 2020: $6.38 million | Fiscal year 2019: $7.20 million | Fiscal year 2018: $8.52 million | Fiscal year 2017: $2.77 million | Fiscal year 2016: $2.65 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: